Project description
Innovative injectable treatment for osteoarthritis
Osteoarthritis (OA) affects millions of people around the globe and is the main cause of disability due to an aging population and the obesity epidemic. Knee joint OA brings severe pain and reduced mobility caused by progressive degradation of bone and cartilage. Scientific data shows that OA treatment requires multi-modal therapeutics. Relevium Medical in Ireland developed Hydrobloc that regenerates the damaged cartilage. provides pain relief and improves joint function through a cushioning lubricant effect. Preclinical studies demonstrated the return to 90% of normal joint function level. The EU-funded ARTIGEL project will conduct validation of the pre-clinical results in large animal models and the development of a business plan for transition to commercialisation.
Objective
Osteoarthritis (OA) is an incurable complex disease affecting an estimated 240 million people globally including 40 million Europeans . OA is the fastest growing cause of disability due to an aging population and the obesity epidemic and affects more people each year than cancer and heart disease. In knee OA progressive degradation of bone and cartilage in the joint results in severe pain and reduced mobility.
Current treatments for Knee OA target only one aspect of the disease, yet most recent scientific data highlight the need for multi-modal therapeutics to treat this complex disease. Furthermore, the limitations of treatments force 80% of patients to rely on strong, addictive pain medication. Through the Hydrolieve ERC proof of concept grant, it was proven that Hydrobloc, statistically significantly reduced pain sensations in an in vivo pain model. These exciting results led Dr Alison Liddy to spin-out Relevium Ltd.
Hydrobloc unique synergistic triple action addresses all aspects of this debilitating disease. Hydrobloc is the only therapeutic that regenerates the damaged cartilage whilst providing immediate, superior pain relief, and improving the physical function of the joint through a cushioning lubricant effect. Pre-clinical studies have proven that Hydrobloc returns the OA joint to 90% of normal (non-OA) physical function.
With this EIC grant, Relevium is partnering with NUI Galway to validate the pre-clinical results in larger animals and preclinically test for other OA indications. Relevium will compile the clinical trial dossier and develop a business model towards the maturation and transition to commercialisation.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine oncology
- medical and health sciences health sciences nutrition obesity
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC - HORIZON EIC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2021-TRANSITIONOPEN-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
H91 PRC6 Gaillimh
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.